South Korea approves Agilent’s diagnostic platform for NSCLC patients

Agilent Technologies Inc. has announced that the South Korea Ministry of Food and Drug Safety (MFDS) has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer (NSCLC) who are suitable for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform. This marks the third approval of the CDx for Agilent in the context of treatment with KEYTRUDA to enable metastatic NSCLC patients’ access to targeted immunotherapy for improved patient outcomes. Dako Omnis is Agilent’s fully automated solution for staining tumour samples that supports lean and flexible workflows integrated into the core of the laboratory interface, providing diagnostic confidence for the right NSCLC patients to facilitate greater choice and accelerate patient care. The new approval in the Asia Pacific region reinforces the proven efficacy of this companion diagnostic test for cancer therapy and enables further immunotherapy options for NSCLC patients, who previously had few and inefficient therapy options.